Pediatric Osteosarcoma Update

Osteosarcoma, the most common type of primary malignant bone tumor, is defined by the presence of malignant mesenchymal cells producing osteoid or immature bone. During this lecture, Dr. Meyers will explain the evolving role of genomic profiling in diagnosing and treating pediatric osteosarcoma, as well as, reviewing the use of histologic necrosis following initial chemotherapy in the treatment of pediatric osteosarcoma.   

Target Audience

Pediatricians, Pediatric Oncologists, Hematologists/Oncologists, Infectious Disease Pediatricians, Pediatric General Internists, Family Physicians, Neonatologists, ED Physicians, Pharmacists and all other interested healthcare providers who care for children with cancer.

Learning Objectives

  • Summarize the meaning and use of histologic necrosis following initial chemotherapy in the treatment of osteosarcoma.  
  • Describe the evolving role of genomic profiling in the diagnosis and treatment of osteosarcoma.
     
Additional information
Bibliography: 
  • MacEwen, E. G., Kurzman, I. D., Rosenthal, R. C., Smith, B. W., Manley, P. A., Roush, J. K., & Howard, P. E. (1989). Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
  • Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., ... & Kleinerman, E. (2008). Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. Journal of clinical oncology, 26(4), 633-638.
  • Whelan, J. S., Bielack, S. S., Marina, N., Smeland, S., Jovic, G., Hook, J. M., ... & Calaminus, G. (2015). EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Annals of Oncology, 26(2), 407-414.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
  • 0.50 Florida Board of Pharmacy
Course opens: 
03/01/2020
Course expires: 
02/28/2023

Paul A. Meyers, M.D. 
Pediatric Oncologist
Chief of Sarcoma Service 
Vice Chair for Clinical Affairs
Memorial Sloan Kettering Cancer Center
New York, New York

Paul A. Meyers, M.D., has indicated that he is a consultant with Boehringer Ingelheim, Genentech and Eli Lilly and is on the speakers bureau with Genentech. He is a shareholder with Amgen. He will include off-label or unapproved product usage in his presentation or discussion.

Symposium Directors
This online course is a highlight from the Kids with Cancer Symposium. Details and enrollment.

Doured Daghistani, M.D.
Symposium Director
Hematologist/Oncologist
Baptist, Homestead and South Miami Hospitals
Miami, Florida

Ziad Khatib, M.D. 
Director of Medical Neuro-Oncology
Division of Pediatric Hematology/Oncology
Clinical Associate Professor
Department of Pediatrics
Florida International University
Kidz Medical Services
Nicklaus Children’s Hospital
Miami, Florida

Doured Dahgistani, M.D., and Ziad Khatib, M.D., symposium directors, have indicated that neither they nor their spouses/partners have relevant financial relationships with commercial interest companies, and they will not include off-label or unapproved product usage in their presentation or discussion.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
  • 0.50 Florida Board of Pharmacy
Please login or register to take this course.

Required Hardware/software

This site is best viewed on the two most recent stable releases of the following browsers for all public pages:

PCs Running Windows

  • Google Chrome (Preferred): Download free web browser for PC, Mac, phone and tablet
  • Internet Explorer (IE 11 and above recommended): You will be prompted to download videos before you are able to view. Click “download” to view video.  After a momentary pause, the recording will play. 
  • Mozilla Firefox: You may be prompted under the “This Connection Is Untrusted” screen to add “cmeonline.baptisthealth.net” and “cdn.baptisthealth.net” under “add exceptions.”

Apple Computers Running OSX

  • Google Chrome (Preferred): Download free web browser for PC, Mac, phone and tablet
  • Safari
  • Mozilla Firefox: You may be prompted under the “This Connection Is Untrusted” screen to add “cmeonline.baptisthealth.net” and “cdn.baptisthealth.net” under “add exceptions.”

This site uses a responsive design, which allows the page layout of elements to change depending on the screen resolution. Certain functionality may change based on the resolution of smaller screens, such as the number of columns in a table.

Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.